Recommendation for Dual Immunotherapy Reimburse...

By João L. Carapinha

June 1, 2026

Zorginstituut Nederland has issued guidance on dual immunotherapy reimbursement for durvalumab combined with tremelimumab in advanced liver cancer, recommending against inclusion in the basic package unless net costs after negotiations stay within...